Search results
Dangerous Drugs Act of 2002, as amended (the "Act"), provides that the Dangerous Drugs Board (the "Board") is the policy-making and strategy-formulating body in the planning and formulation of policies and programs on drug prevention and control; WHEREAS, Section 2 of the Act provides that it is a declared policy of the State
Dangerous Drugs Act of 2002, as amended (the "Act"), provides that the Dangerous Drugs Board (the "Board") to be the policy—making and strategy-formulating body in the field of drug prevention and control; WHEREAS, Section 84 (a) of the Act provides for the Philippine Drug
dangerous drugs board board regulation no. 6 series of 2021 guidelines on the implementation of section 20 of ra 9165, or the comprehensive dangerous drugs act of 2002, as amended, specifically the last paragraph thereof, covering the necessary cost for the maintenance and preservation of seized item/s pending trial of the case,
b. Board – refers to the Dangerous Drugs Board (DDB) under Section 77, Article IX of RA 9165. c. Board Regulation – refers to Board Regulation No. 3, Series of 2003. d. License – a written permission or authorization. e. PDEA – refers to the Philippine Drug Enforcement Agency (PDEA) created pursuant to Section 82, Article IX of RA 9165. f.
DANGEROUS DRUGS BOARD 3/F, DDB- PDEA Building, NIA Northside Road, National Government Center, Brgy. Pinyahan, Quezon City, NCR, Philippines P.o BoxNo. 3682 Manila, Tel. No. 929-1753, E-mail : v. h SUBJECT: WHEREAS BOARD REGULATION No. 4 Series of 2016 OPLAN SAGIP - GUIDELINES ON VOLUNTARILY SURRENDER OF DRUG USERS AND DEPENDENTS AND MONITORING
in this Regulation: Board – the Dangerous Drugs Board. Controlled precursors and essential chemicals – include those listed in Tables I and II of the 1988 UN Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances and made an integral part of RA 9165, as well as those classified as such by the Dangerous Drugs Board.
WHEREAS, the Dangerous Drugs Board (DDB) promulgated Board Regulation No. 2, Series of 2003, providing for the Implementing Rules and Regulations Governing Accreditation of Drug Testing Laboratories in the Philippines; WHEREAS, the Drug Testing Operations Management and Information Systems (DTOMIS) was adopted by the DOH and approved by the DDB to
